Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Study Details
Study Description
Brief Summary
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Single Group Assignment Adults with health check-ups at multiple health examination centers across China |
Diagnostic Test: Fibrotouch
Fibrotouch will be performed showing the stiffness and fat content of liver
|
Outcome Measures
Primary Outcome Measures
- To investigate the prevalence of MAFLD among adults at multiple health examination centers across China. [through study completion, an average of 1 year]
MAFLD means metabolic dysfunction-associated fatty liver disease
Secondary Outcome Measures
- To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²). [through study completion, an average of 1 year]
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
- To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²) [through study completion, an average of 1 year]
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
- To assess the prevalence of type 2 diabetes among patients with MAFLD. [through study completion, an average of 1 year]
MAFLD means metabolic dysfunction-associated fatty liver disease
- To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD. [through study completion, an average of 1 year]
MAFLD means metabolic dysfunction-associated fatty liver disease
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged between 18 and 75, both sex;
-
Able to sign informed consent.
Exclusion Criteria:
- Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Bejing Tsinghua Chang Gung Hospital | Beijing | Bejing | China | 100034 |
Sponsors and Collaborators
- Beijing Tsinghua Chang Gung Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. Review.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. Review.
- CG-MAFLD-001